EQS-News: HAEMATO AG with a strong start into the year 2023:   Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result

HAEMATO AG with a strong start into the year 2023:  
Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result              
 

• In the first quarter of 2023, preliminary IFRS consolidated revenue increased by 25.3% to EUR 68.4 million compared to the same quarter of 2022 (EUR 54.4 million).             
   
• The result from ordinary activities (EBITDA) was increased by around 55% to EUR 3.57 million.             
   
• The operating result (EBIT) could even be increased by 73.5% to 3.42 million euros.  
   

Berlin, 31 May 2023 - HAEMATO AG (ISIN: DE000A289VV1) has continued its profitable growth course in the new year and increased its revenue in the first quarter of 2023 by EUR 13.8 million compared to the same quarter of 2022 to EUR 68.4 million. This represents a growth in turnover of 25.3 % compared to the same period of the previous year.

The result from ordinary activities (EBITDA) rose from EUR 2.31 million in Q1/22 to EUR 3.57 million, an increase of around 55%. The operating result (EBIT) increased significantly by EUR 1.45 million from EUR 1.97 million in Q1/22 to EUR 3.42 million in this period. The increase amounts to 73.5% and results in particular from the further expansion of the profitable "Lifestyle & Aesthetics" business segment.

"We are continuing on a successful path of steadily improving our EBIT margin through consistent product management and implementation of the efficiency improvement programmes. The EBIT margin was increased to 5.0% in the first quarter of 2023, this is even higher than the margin of 3.9% from the business year 2021, which was particularly influenced by the lucrative Corona test business," says Patrick Brenske, CEO of HAEMATO AG.

The new segment "Lifestyle & Aesthetics" continues to contribute disproportionately to the result and will be expanded in the future. Preparations for the approval of a proprietary botulinum toxin for the European market continue to proceed according to plan. CEO Atilla Strauss explains: "The application to conduct a clinical trial was submitted to the competent authorities at the end of January 2023. We expect the approval to be granted in 2025 if the clinical trial proceeds normally".

The annual report for the year 2022 was published on 17 May 2023. The Executive Board and the Supervisory Board propose to the Annual General Meeting a dividend of EUR 1.20 per dividend-bearing share, an increase by EUR 0.10.

This year's Annual General Meeting will take place as a presence event on Tuesday, 18 July in Berlin.              

About HAEMATO:

HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de.

Contact:

HAEMATO AG, Investor Relations

Telefon: +49 (0)30 897 30 86 70

[email protected]